PubMed=1355757; DOI=10.1002/ijc.2910520217
Shimizu Y., Demetris A.J., Gollin S.M., Storto P.D., Bedford H.M., Altarac S., Iwatsuki S., Herberman R.B., Whiteside T.L.
Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.
Int. J. Cancer 52:252-260(1992)

CLPUB00275
Zach S., Birgin E., Ruckert F.
Primary cholangiocellular carcinoma cell lines.
J. Stem Cell Res. Transplant. 2:1013-1013(2015)

PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442
Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C., Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K., Greninger P., McDermott U., Garnett M.J., Jenkins R.L., Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y., Goyal L., Ferrone C.R., Zhu A.X., Joung J.K., Shokat K.M., Benes C.H., El-Bardeesy N.
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.
Cancer Discov. 6:727-739(2016)

PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007
Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y., Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S., Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.
Development and characterization of human primary cholangiocarcinoma cell lines.
Am. J. Pathol. 192:1200-1217(2022)